Renewal of Provisional Consent to the Distribution of a New Medicine Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicines set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Danthron 25 mg, poloxamer 188 200 mg per 5 mL in 100 mL and 300 mL Suspension, oral Regent Laboratories Limited, North Acton, London, England and Universal Products Limited, Lytham, Lancashire, England Codalax Danthron 75 mg, poloxamer 188 1 g per 5 mL in 10 mL and 300 mL Suspension, oral Regent Laboratories Limited, North Acton, London, England and Universal Products Limited, Lytham, Lancashire, England Codalax Forte Note: This consent is valid for two years from the 30th of July 1996. Dated this 29th day of October 1996. KAREN O. POUTASI (Dr), Director-General of Health, pursuant to delegation given by the Minister of Health on the 18th day of January 1996.